Evidence map›Paper›PMID 29736839›Full record

ArticleDigestive diseases and sciences2018

Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.

Adam V Weizman, Robyn Sharma, N M Afzal, Wei Xu, Scott Walsh, Joanne M Stempak, Geoffrey C Nguyen, Ken Croitoru, A Hillary Steinhart, Mark S Silverberg

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Adam V WeizmanDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 437-600 University Avenue, Toronto, ON, M5G 1X5, Canada. adam.weizman@sinaihealthsystem.ca.
Robyn SharmaDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 437-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
N M AfzalDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 437-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
Wei XuDepartment of Public Health Sciences, University of Toronto, 610 University Avenue, Suite 10-512, Toronto, ON, M5G 2M9, Canada.
Scott WalshDivision of Dermatology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room M1-724, Toronto, ON, M4N 3M5, Canada.
Joanne M StempakDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 411-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
Geoffrey C NguyenDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 437-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
Ken CroitoruDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 437-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
A Hillary SteinhartDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 445-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
Mark S SilverbergDivision of Gastroenterology, Department of Medicine, Mount Sinai Hospital IBD Centre, University of Toronto, 441-600 University Avenue, Toronto, ON, M5G 1X5, Canada.
University of Toronto · CAMount Sinai Hospital · CAHealth Sciences Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParadoxical development of psoriasis in patients on anti-TNF agents has been increasingly reported.

aimThe aim was to characterize the prevalence and clinical characteristics of anti-TNF-associated psoriasis in a large cohort of inflammatory bowel disease patients.

methodsMedical records of patients with Crohn's disease or ulcerative colitis treated with anti-TNF therapy at a single, tertiary IBD center were identified between 2004 and 2016. Patients identified as having developed psoriasis while on anti-TNF underwent detailed retrospective review of dermatologic features and changes in IBD treatment prompted by the development of psoriasis.

resultsAmong 676 patients treated with anti-TNF (infliximab or adalimumab), the incidence of psoriasis was 10.7% (N = 72). Female gender (OR 1.88 [95% CI 1.12-3.17], p = 0.017), stricturing or fistulizing Crohn's disease (OR 1.83 [95% CI 1.04-3.21], p = 0.036) and upper GI Crohn's disease (OR 3.03 [95% CI 1.06-8.33], p = 0.039) were associated with psoriasis development. The median time to psoriasis onset was 569 days from initiation of anti-TNF, with onset occurring earlier in patients who developed psoriasis on adalimumab versus infliximab (457 vs. 790.5 days, p = 0.008). Overall, in 15/72 (20.8%), cases, cessation of the anti-TNF was required as a result of psoriasis. Plaque psoriasis was the most common type of psoriatic lesion (75%). Topical corticosteroids were the most common treatment for psoriasis.

conclusionWe report a high incidence of anti-TNF-associated psoriasis that was associated with female gender, foregut disease location, and fistulizing and stricturing disease behavior. More prospective studies and genetic analyses evaluating possible pathophysiologic underpinnings of this problem are needed.

Indexed as

AdalimumabAdultCohort StudiesCrohn DiseaseFemaleGastrointestinal AgentsHumansInflammatory Bowel DiseasesInfliximabMaleMiddle AgedPsoriasisRetrospective StudiesTumor Necrosis Factor-alphaAdalimumabGastrointestinal AgentsInfliximabTumor Necrosis Factor-alphaAnti-tumor necrosis factorCrohn’s diseaseEpidemiologyInflammatory bowel diseasePsoriasisUlcerative colitis

Identifiers

PMID29736839
OpenAlexW2802424903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.